20-F/A: ALR Technologies SG Ltd. Files Amendment to 20-F Annual Report Addressing SEC Comments

ALR Technologies SG Ltd. amends its 20-F report to address SEC comments, with no changes to the original financial statements.

Summary

• ALR Technologies SG Ltd. filed Amendment No. 1 on Form 20-F/A to amend its annual report for the fiscal year ended December 31, 2023, addressing comments from the SEC staff.
• The amendment does not modify or update the financial statements in the original filing and does not reflect any events occurring after April 30, 2024.
• The company is furnishing certifications required under Section 302 and Section 906 of the Sarbanes-Oxley Act of 2002 as exhibits to the amendment.
• The company had an accumulated deficit of $120,108,400 at December 31, 2023.
• The company recorded net losses of $7,474,514 for the year ended December 31, 2023.
• The company requires additional financing to become a commercially viable enterprise.
• The company generated $25,536 in revenue during the year ended December 31, 2023.
• The company is evaluating CGM systems to bundle with its Diabetes Solution product for human health.
• The company is targeting to offer its Diabetes Solution product bundled with CGM with pricing to compete with the standalone BGM offerings.
• The company is focusing its efforts on introducing and marketing its GluCurve products to veterinary clinics, animal health companies, distributors of animal health products and pharmaceutical companies with animal health products.

Sentiment

Score: 3

Explanation: The document highlights significant financial challenges, including substantial losses and a severe working capital deficiency, raising concerns about the company's ability to continue as a going concern. While there are some positive aspects, the overall tone is negative due to the financial risks and uncertainties.

Positives

• The company is actively evaluating CGM systems to bundle with its Diabetes Solution product for human health, potentially enhancing its product offering.
• The company is targeting a competitive pricing strategy for its Diabetes Solution product bundled with CGM, which could drive market adoption.

Negatives

• The company's accumulated deficit reached $120.1 million as of December 31, 2023.
• Net losses for the year ended December 31, 2023, amounted to $7.47 million.
• The company has a severe working capital deficiency and requires additional financing to become commercially viable.
• The company has a significant amount of debt that is either due on demand or in default.

Risks

• The company's ability to continue as a going concern is dependent on obtaining financing and achieving profitable operations.
• The company faces the risk of legal action from creditors regarding delinquent accounts payable and promissory notes.
• The company's success depends on securing supply of BGM or CGM that function according to specifications and customer expectations and its ability to supply its products in compliance with the FDAs Quality System Regulation and other regulatory requirements.
• The company's success depends, in part, on securing and developing relationships with, and on the efforts of, third-party distributors to sell and distribute its Diabetes Solution and GluCurve products.

Future Outlook

The company intends to improve its financial condition by increasing revenues through new markets, expanding its sales force, forming strategic arrangements, and reducing expenses.

Industry Context

The document relates to a company in the diabetes management and animal health sectors, which are experiencing rapid technological changes and increasing competition.

Legal Proceedings

• The company is subject to legal proceedings related to overdue promissory notes and accrued interest.
• A default judgment was entered against the company in regards to one of the above noted judgments totaling $552,000, consisting of the principal amount of $300,000 and accrued interest of $252,000, as of the date of the Civil Summons.
• Another default judgment was entered against the company in regard to one of the above noted judgments totaling $255,000, consisting of the principal amount of $125,000 and accrued interest of $130,000, as of the date of the Civil Summons.

Related Party Transactions

• The company has significant related party transactions, including lines of credit, promissory notes, and a loan payable to related parties.
• The CEO and VP of Corporate Development are significant creditors of the company.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment.
• Creditors face the risk of non-payment.
• Employees face uncertainty regarding job security.
• Customers may be concerned about the company's ability to continue providing products and services.

Next Steps

• The company will seek to obtain creditors consents to delay repayment of these loans until it is able to replace these financings with funds generated by operations, replacement debt, or from equity financings through private placements or the exercise of options and warrants.
• The company will seek to secure CGM system supply during 2024, subsequent to which it can initiate a clinical trial and prepare for a subsequent clearance from regulatory authorities to sell in key target countries for roll out.

Key Dates

Keywords

financial statements, amendment, ALR Technologies, SEC comments, going concern, Diabetes Solution, GluCurve, CGM, financial results, losses, revenue, financing